Ballentine Partners, LLC Ab Cellera Biologics Inc. Transaction History
Ballentine Partners, LLC
- $6.57 Billion
- Q2 2025
A detailed history of Ballentine Partners, LLC transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Ballentine Partners, LLC holds 23,689 shares of ABCL stock, worth $92,387. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,689Holding current value
$92,387% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding ABCL
# of Institutions
152Shares Held
132MCall Options Held
156KPut Options Held
346K-
Baker Bros. Advisors LP New York, NY27.5MShares$107 Million0.73% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL15.7MShares$61.1 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA13.4MShares$52.1 Million0.01% of portfolio
-
Baillie Gifford & CO11.2MShares$43.7 Million0.02% of portfolio
-
Voya Investment Management LLC Atlanta, GA10.6MShares$41.4 Million0.03% of portfolio
About AbCellera Biologics Inc.
- Ticker ABCL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 285,139,008
- Market Cap $1.11B
- Description
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...